Medical oncologist Dr. Joseph Leach provides an overview of how doctors
treat ALK-rearranged lung cancer. He discusses
targeted therapies for
ALK mutations including alectinib, brigatinib, and lorlatinib, which are effective in controlling cancer. He explains that cancer cells can become resistant to targeted therapies, so it is important to
repeat biomarker testing if treatment stops working at any time and to also consider participating in
clinical trials.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.